摘要
目的探讨胸腺肽α1治疗重型肝炎的临床疗效。方法将重症肝炎患者38例分为研究组和对照组,研究组在常规治疗基础上加用胸腺肽α1治疗,评价两组临床疗效。结果两组治疗后TBIL和ALT明显下降,白蛋白和PTA显著升高,且研究组升高更明显(P<0.01)。研究组感染例数少于对照组,无死亡病例,差异均有统计学意义(P<0.05或P<0.01)。结论胸腺肽α1治疗重型肝炎能够促进肝功能的恢复,减少感染的发生。
Objective To discuss clinical efficacy of Thymosin α1 in treatment of severe hepatitis. Methods Secleted 38 cases with severe hepatitis were divided into study group and control group. Study group was treated by Thymosin α1 on base of commom trertment. The clinical efficacy of two groups were observed. Results TBIL and ALT in two groups were decreased apparently after therapy; Albumin and PTA in two groups were increased apparently after ther- apy; And study group increased more （P 〈 0.01）. Cases with infection of study were less than control group, and study group without death case （P 〈 0.05 or P 〈 0.01 ）. Conclusion Thymosin α1 in treatment of can promote recovery of liv- er function, reduce infection occurring.
出处
《中国现代医生》
2013年第6期52-53,共2页
China Modern Doctor
